A Randomized, Double-Blind, Losartan-Controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg-120mg in Patients With Mild to Moderate Essential Hypertension.

Trial Profile

A Randomized, Double-Blind, Losartan-Controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg-120mg in Patients With Mild to Moderate Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Fimasartan (Primary) ; Losartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
    • 28 Feb 2012 Results published in Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top